22157.jpg
Outlook on the TIL Therapies Global Market to 2035: by Target Indication, Key Players and Key Geographical Regions
01 févr. 2023 06h33 HE | Research and Markets
Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts,...
AIMLogo.jpg
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
17 janv. 2023 08h45 HE | AIM ImmunoTech Inc.
OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
07 déc. 2022 07h30 HE | HCW Biologics, Inc
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
28 nov. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of...
logo_tau.png
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
22 nov. 2022 16h02 HE | Alpha Tau Medical Ltd.
JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha...
AIMLogo.jpg
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
15 nov. 2022 07h00 HE | AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Third Quarter 2022 Financial Results
07 nov. 2022 16h01 HE | FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Participate at Stifel 2022 Healthcare Conference
01 nov. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Third Quarter 2022 Financial Results
24 oct. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also...
logo_tau.png
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
21 oct. 2022 16h01 HE | Alpha Tau Medical Ltd.
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge - - Health Canada...